For the quarter ending 2025-10-31, BCTXW had -$7,779,796 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-10-31 | 2025-07-31 |
|---|---|---|
| Net loss for the period | -8,278,328 | -26,556,140 |
| Amortization | 3,818 | 15,271 |
| Financial expenses, net | 89,487 | 56,473 |
| Depreciation | 22,839 | 91,356 |
| Share-based compensation | 294,686 | 776,879 |
| Equity losses | -44,830 | -224,212 |
| Change in fair value of the warrant liability | 69,201 | -758,364 |
| Decrease (increase) in amounts receivable | - | -733,629 |
| Decrease in prepaid expenses | - | -492,279 |
| Decrease in amounts receivable and prepaid expenses | 887,860 | - |
| Decrease in accounts payable | -1,154,788 | -3,887,078 |
| Increase in accrued expenses and other payables | 494,573 | 753,909 |
| Total cash flow from operating activities | -7,704,796 | -28,170,520 |
| Purchase of short-term investments, net | - | 7,316,000 |
| Equity investment in bc therapeutics | 75,000 | 330,000 |
| Total cash flow from investing activities | -75,000 | -7,646,000 |
| Proceeds from exercise of warrants | - | 821,015 |
| Proceeds from issuance of shares, net of issuance costs | - | 44,627,224 |
| Net cash provided by financing activities | - | 45,448,239 |
| Increase (decrease) in cash and cash equivalents | -7,779,796 | 9,631,719 |
| Cash and cash equivalents at beginning of period | 10,493,808 | 862,089 |
| Cash and cash equivalents at end of period | 2,714,012 | 10,493,808 |
BriaCell Therapeutics Corp. (BCTXW)
BriaCell Therapeutics Corp. (BCTXW)